ReviewFuture cardiology2025
The effect of renal denervation in microcirculation: focusing on coronary microvascular dysfunction.
Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reframing renal denervation: from blood pressure reduction to autonomic disease modification-a state-of-the-art review.Clinical hypertension · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial hypertension is one of the most prevalent cardiovascular pathologies worldwide. Considering the increased rates of uncontrolled hypertension and treatment non-adherence, catheter-based methods, with the most prominent being renal denervation, have been recently included in international guidelines for the management of the pathology, naming the method the third pillar in hypertension management. However, sympathetic overactivation is not only a major pathophysiologic driver in hypertension, but in other cardiovascular pathologies as well. Considering the effect of renal denervation in hypertension-mediated target organ damage, as well as the pleotropic effects of this modality, recent evidence have evaluated the modality in coronary microvascular dysfunction (CMD). Interestingly, despite preclinical data showcase a benefit of renal denervation in microcirculatory homeostasis, with enhancement of endothelial-mediated vasodilation and reduction of inflammation, these effects have failed to be translated into clinical benefit, with the limited, to date, non-interventional studies in coronary microcirculation reporting neutral effects. Therefore, this review aims to delineate the pathophysiological processes which relate microvascular dysfunction with hypertension, discuss the effect of the procedure in hypertension-mediated target organ damage, analyze preclinical and clinical data on the safety and efficacy of renal denervation in improving microcirculatory indices, as well as provide future directions for this novel field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.